In 2010, the American Society of Clinical Oncology and College of American Pathologists published guidelines for determining hormone receptor status in breast tumors, with a cutoff of 1% positive cells defining ER positive status [20] with updated guidelines published in 2020 recommending that tumors with 1–10% ER positive cells should be classified as ER low positive [21]. This evidence concerns the gene NR4A1 and breast neoplasm.